Sinopharm Group Balance Sheet Health
Financial Health criteria checks 5/6
Sinopharm Group has a total shareholder equity of CN¥122.4B and total debt of CN¥95.6B, which brings its debt-to-equity ratio to 78.1%. Its total assets and total liabilities are CN¥429.6B and CN¥307.2B respectively. Sinopharm Group's EBIT is CN¥20.9B making its interest coverage ratio 11.4. It has cash and short-term investments of CN¥43.3B.
Key information
78.1%
Debt to equity ratio
CN¥95.61b
Debt
| Interest coverage ratio | 11.4x |
| Cash | CN¥43.33b |
| Equity | CN¥122.43b |
| Total liabilities | CN¥307.15b |
| Total assets | CN¥429.58b |
Recent financial health updates
Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet
Dec 30
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Recent updates
Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet
Dec 30At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?
Nov 26Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥382.4B) exceed its short term liabilities (CN¥283.2B).
Long Term Liabilities: 1099's short term assets (CN¥382.4B) exceed its long term liabilities (CN¥23.9B).
Debt to Equity History and Analysis
Debt Level: 1099's net debt to equity ratio (42.7%) is considered high.
Reducing Debt: 1099's debt to equity ratio has reduced from 97.2% to 78.1% over the past 5 years.
Debt Coverage: 1099's debt is well covered by operating cash flow (20.4%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (11.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 08:37 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinopharm Group Co. Ltd. is covered by 42 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Mann | Barclays |
| Derrick Sun | BNP Paribas Securities (Asia) |
| Bo Li | BofA Global Research |